Reven Pharmaceuticals, Inc.   Report issue

For profit Phase 2
Founded: Sarasota FL United States (1999)

Organization Overview

First Clinical Trial
2017
NCT03041259
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Reven Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

dexamethasone (1 trial)

multivitamins (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ischemia (Phase 2)

Peripheral Arterial Disease (Phase 2)

Peripheral Vascular Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2